Data / Form D filings / Farapulse, Inc.
Farapulse, Inc.: Form D filings
Farapulse, Inc., a biotechnology company in Menlo Park, CA, filed 9 Form D notices with the SEC between 2014 and 2018. The latest, on August 13, 2018, reports $12 million sold of a $12 million offering to 32 investors.
Find out what Farapulse, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3715 HAVEN AVENUE, SUITE 110, Menlo Park, CA, 94025
- Phone
- (650) 556-5069
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2014
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1609573
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2018 | New notice | $12,000,000 | $11,999,993 | $7 | 32 | May 31, 2018 | sec.gov |
| Jul 11, 2017 | New notice | $5,000,000 | $5,000,000 | $0 | 2 | Jun 14, 2017 | sec.gov |
| Mar 3, 2016 | New notice | $23,999,173 | $14,999,173 | $9,000,000 | 35 | Feb 18, 2016 | sec.gov |
| Oct 13, 2015 | Amendment | $8,500,000 | $4,300,080 | $4,199,920 | 34 | May 30, 2014 | sec.gov |
| Feb 23, 2015 | Amendment | $5,500,000 | $2,175,080 | $3,324,920 | 24 | May 30, 2014 | sec.gov |
| Jan 8, 2015 | Amendment | $3,750,000 | $1,675,080 | $2,074,920 | 21 | May 30, 2014 | sec.gov |
| Oct 10, 2014 | Amendment | $2,500,000 | $750,080 | $1,749,920 | 12 | May 30, 2014 | sec.gov |
| Jul 10, 2014 | Amendment | $2,000,000 | $400,080 | $1,599,920 | 8 | May 30, 2014 | sec.gov |
| Jun 9, 2014 | New notice | $2,000,000 | $400,080 | $1,599,920 | 8 | May 30, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James Eadie | Director | |
| Robert Weisskoff | Director | |
| Christopher Kaster | Director | |
| Allan Zingeler | Executive Officer, Director | |
| Andrew Elbardissi | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
Every Form D from the week of Aug 13, 2018 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Farapulse, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.